CFO Jackson buys 2.5K shares at $2.00; stock down 96.2% from $40.56 high; 3 other insiders bought in past 14 days
Jackson Andrew C., CFO of Calidi Biotherapeutics, purchased 2,500 shares at $2.00 on 2025-08-21, representing his first equity position in the company. The purchase occurs after a severe equity drawdown: the stock is currently at $1.56, down -96.2% from its 52-week high of $40.56 and down -82.2% over the past 30 days. Notably, three other insiders also purchased shares within the past 14 days, forming a cluster buy pattern. The company remains unprofitable with a net income of $-5.7M over its most recent full fiscal year, and its market capitalization stands at $5.3M, raising questions about whether the cluster purchases reflect conviction or are driven by other factors in a distressed financial context.